The peptide market is forming faster than the trust layer.

Defensible market facts

• Grand View Research publicly reports Australia peptide therapeutics revenue of US$1.906B in 2025, projected to reach US$3.711B by 2033, with 7.8% CAGR from 2026 to 2033.
• McDermott's April 2026 peptide regulation deck cites the global peptide therapeutics market at US$140.86B in 2025 and US$294.58B projected for 2033.
• TIME and NPR both reported in February 2026 that social media, wellness influencers, and celebrity discussion are pushing peptides into mainstream awareness.
• The Week and GZERO reported that US imports of hormone and peptide compounds from China reached US$328M in the first three quarters of 2025, up from US$164M in the same period a year earlier.
• Brandwatch-based looksmaxxing coverage reported more than 806,000 mentions from September 2025 to early 2026, showing how appearance-led self-optimization demand has become a search and social channel.

Initial evidence base

The local March 2026 crawl tracked Australian and New Zealand peptide storefront candidates, Shopify stores, custom storefronts, WordPress stores, and adjacent wellness operators. This static launch uses that crawl as a source snapshot, not as final live proof.

What the report will measure

• How many vendors publish batch records before checkout.
• How many COAs are current and tied to a batch.
• How many vendors show Australian operation evidence beyond copy.
• How many suppliers offer payment recourse if the order fails.
• How many correction requests receive useful responses.

The commercial thesis

The commercial opening is not louder peptide advertising. It is owning the proof moment before a buyer trusts any store. That only compounds if the rubric, ownership, correction path, and evidence standard are public.

Reference sources

• Grand View Research - Australia Peptide Therapeutics Market Size & Outlook: Public page states Australia peptide therapeutics revenue of US$1,906.3M in 2025, projected US$3,711.1M by 2033, at 7.8% CAGR from 2026 to 2033.
• McDermott Will & Schulte - Peptides Under the Microscope, April 2026: Presentation cites global peptide therapeutics at US$140.86B in 2025 and US$294.58B projected for 2033.
• TIME - What to Know About Anti-Aging Peptide Shots Flooding Social Media: Reports that wellness enthusiasts, biohackers, influencers, and celebrities are driving mainstream peptide attention while many products remain grey-market or unapproved.
• The Week - The regulation issues with grey-market peptides: Summarizes reporting that US imports of hormone and peptide compounds from China reached US$328M in the first three quarters of 2025, up from US$164M in the prior-year period.
• GZERO Media - How China is supplying America's biohacking craze: Reports the same near-doubling of US hormone and peptide compound imports from China in 2025.
• NPR / The Public's Radio - Influencers are promoting peptides: Reports influencer-driven peptide promotion and uncertainty around science, income disclosures, and product claims.
• Looksmaxxing exposes the darker side of glow-up culture: Reports a Brandwatch analysis of more than 806,000 looksmaxxing mentions from September 2025 to early 2026, with mostly negative sentiment.
• Hone Health - 26 Longevity Trends That Will Define 2026: Lists peptides and regenerative aesthetics as watched 2026 longevity and recovery trends.